# BETAMI-DANBLOCK is representatief: bètablokker-effect ook geldig in echte Noorse infarct-populatie

*geplaatst 2026-06-02 · Algemeen · European heart journal · doi 10.1093/eurheartj/ehag348 · https://hartvaat.nl/2026/05/25/betami-danblock-is-representatief-betablokker-effect-ook-geldig-in-echte-noorse-/*

Vergelijking van de deelnemers in de BETAMI- (n=2.867) en DANBLOCK-studies (n=2.707) met de Noorse landelijke infarctregistratie NORMI (n=20.804) — alle patiënten met recent infarct, LVEF ≥40% en zonder hartfalen. De NORMI-patiënten waren gemiddeld ouder (66 versus 63 jaar) en hadden vaker diabetes, eerdere coronaire ziekte en LVEF 40-49%. De absolute 3-jaars risico's waren hoger in NORMI (mortaliteit/MI 12,0%) dan in de trials (7,7-7,8%). Een transportabiliteitsanalyse (waarbij de trial-populatie werd geherweegd naar de NORMI-karakteristieken) liet zien dat het behandeleffect van bètablokkers consistent bleef. De BETAMI-DANBLOCK-bevindingen zijn dus generaliseerbaar naar de bredere Noorse — en daarmee Europese — infarct-populatie.

## English: 

Comparison of participants in the BETAMI (n=2,867) and DANBLOCK (n=2,707) trials with the Norwegian nationwide myocardial infarction registry (NORMI, n=20,804) — all patients with recent MI, LVEF ≥40% and no heart failure. NORMI patients were older on average (66 vs 63 years) and had more diabetes, prior coronary disease and LVEF 40-49%. Absolute 3-year risks were higher in NORMI (mortality/MI 12.0%) than in the trials (7.7-7.8%). A transportability analysis (reweighting the trial population to NORMI characteristics) showed that the beta-blocker treatment effect remained consistent. BETAMI-DANBLOCK findings therefore generalise to the broader Norwegian — and by extension European — post-MI population.

## Abstract (original, from the publication)

BACKGROUND AND AIMS: In patients with myocardial infarction (MI), no heart failure, and left ventricular ejection fraction (LVEF) ≥ 40%, the combined BETAMI-DANBLOCK trial showed that beta-blockers reduced the risk of all-cause mortality or major adverse cardiovascular events. This study evaluated the representativeness of the trial. METHODS: Participants in BETAMI (n = 2867) and DANBLOCK (n = 2707) were compared with a cohort of revascularized MI patients with LVEF ≥40%, and no heart failure from the Norwegian Myocardial Infarction Registry (the NORMI cohort)(n = 20 804). Baseline characteristics were evaluated, and absolute risks of all-cause mortality and/or MI were estimated. A transportability analysis was conducted by weighting the BETAMI-DANBLOCK population according to the NORMI cohort. RESULTS: Median age was 66 years (interquartile range [IQR]: 57-74) in the NORMI cohort and 63 years (IQR: 55-70) in BETAMI and DANBLOCK. Patients in the NORMI cohort had a higher prevalence of diabetes, previous coronary artery disease, and LVEF 40-49%, compared with trial participants. At 3-year follow-up, the absolute risk of all-cause mortality or MI was 12.0% in the NORMI cohort, 7.7% in BETAMI, and 7.8% in DANBLOCK. Corresponding risks of MI were 6.3%, 5.6%, and 4.3%, respectively. The treatment effects of beta-blockers were similar when the trial population was weighted according to the characteristics of the NORMI cohort. CONCLUSIONS: Compared with the NORMI cohort, participants in BETAMI and DANBLOCK were younger, had a lower proportion of certain comorbidities, and experienced a lower risk of all-cause mortality and MI. Despite these differences, the effect of beta-blockers remained consistent when the trial population was weighted according to the NORMI cohort.

Auteurs: Anna Meta Dyrvig Kristensen, Jarle Jortveit, Therese Holmager, Dan Atar, Michael Hecht Olsen, Arnhild Bakken, Terje Steigen, Henrik Schirmer, Thor Edvardsen, Alf Inge Larsen, Jan Erik Otterstad, Eva Prescott, John Munkhaugen, Sigrun Halvorsen

---
Bron: European heart journal, https://doi.org/10.1093/eurheartj/ehag348. Bijgewerkt 2026-07-03T13:31:54Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.